To examine the role of JUN and AXL/MerTK in efferocytosis of TAMs, mice bearing BLCA were treated with either AP-1 inhibitor T-5224 or AXL/MerTK inhibitor R428. Here, MERTK is linked to bladder transitional cell carcinoma.